Autopsy report · NCT05161936

A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels

“Study terminated early due to low enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 9 months before it stopped.
• 2 participants enrolled.
• Results were posted on the registry 1 year 7 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Alnylam Pharmaceuticals

Sponsor type

Industry

Conditions

Recurrent Calcium Oxalate Kidney Stone Disease; Elevated Urinary Oxalate Levels

Interventions

Lumasiran; Placebo

Participants

2

Sites

31

Countries

Belgium, Italy, Spain, Switzerland, United Kingdom, United States

Trials that died the same way

• Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)
  “Study was terminated due to low enrollment” (93% match in meaning)
• Effect of Pradaxa vs Warfarin on Bone Mass and Bone Turnover Markers
  “Study was terminated early due to low enrollment numbers.” (93% match in meaning)
• MIRACLE EF Clinical Study
  “The study was terminated early due to low enrollment.” (92% match in meaning)
• Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)
  “Study terminated due to low enrollment.” (91% match in meaning)
• Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma
  “the study was terminated early due to poor enrollment” (90% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.